Item 2.02 Results of Operations and Financial Condition.

On March 29, 2023, Pieris Pharmaceuticals, Inc. (the "Company") issued a press release announcing certain financial results for the quarter ended December 31, 2022. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.

The information set forth under this "Item 2.02. Results of Operations and Financial Condition," including Exhibit 99.1 furnished hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

--------------------------------------------------------------------------------

Item 7.01 Regulation FD Disclosure.

Furnished hereto as Exhibit 99.2 is the March 2023 Investor Presentation of the Company.

The information set forth under this "Item 7.01. Regulation FD Disclosure," including Exhibit 99.2 furnished hereto, shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing except as shall be expressly set forth by specific reference in such filing.


--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



99.1   Press Release, dated March 29, 2023.


99.2   Investor Presentation, dated March 2023.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses